Cargando…
P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA
Autores principales: | Luo, Wenjing, LI, Chenggong, Zhang, Yinqiang, Wang, Xindi, Wu, Zhuolin, Kou, Haiming, Lu, Cong, Liao, Danying, Chen, Zejian, Chen, Caiqin, Wu, Lijun, Xiong, Wei, Deng, Jun, Hu, Yu, Mei, Heng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430464/ http://dx.doi.org/10.1097/01.HS9.0000972460.43253.39 |
Ejemplares similares
-
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023) -
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
por: Mei, Heng, et al.
Publicado: (2021) -
Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia
por: Zhang, Yinqiang, et al.
Publicado: (2022) -
IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy
por: Wang, Xindi, et al.
Publicado: (2023) -
P1404: IL-10 PLUS THE EASIX SCORE PREDICT BLEEDING EVENTS AFTER ANTI-CD19 CAR T-CELL THERAPY
por: Wang, Xindi, et al.
Publicado: (2023)